SCHEMBL4763808

SCHEMBL4763808

CCCCN(CCC)c1ccn[c]n1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 2/20 0.34
LMNA P02545 1/20 0.34
UTS2R Q9UKP6 1/20 0.33
HTT P42858 2/20 0.33
NCOA1 Q15788 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NCOA3 Q9Y6Q9 1/20 0.33
MAPT P10636 2/20 0.31
MAPK1 P28482 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
CRHR1 P34998 1/20 0.31
ELANE P08246 1/20 0.31
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
NR1H2 P55055 1/20 0.30
NR1H3 Q13133 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4724804 0.96 LMNA (0.35) LMNAUTS2RHTTNCOA1SMN1; SMN2
SCHEMBL4722558 0.93 HCAR3 (0.38) HCAR3HTT
SCHEMBL4724811 0.90 MAPT (0.35) LMNAUTS2RHTTNCOA1SMN1; SMN2
SCHEMBL4720137 0.86 CYP2D6 (0.33) HCAR3
SCHEMBL4723754 0.81 HRH3 (0.38) HCAR3MAPTTDP1KDM4EALDH1A1
SCHEMBL4723694 0.80 GBA1 (0.37) SMN1; SMN2MAPK1TDP1KDM4EALDH1A1
SCHEMBL4722993 0.77 HCAR3 (0.39) HCAR3
SCHEMBL15415594 0.75 CYP2D6 (0.30)
SCHEMBL4723357 0.70 LMNA (0.32) HCAR3LMNAHTTNCOA1SMN1; SMN2
SCHEMBL14229048 0.70 UTS2R (0.37) HCAR3LMNAUTS2RHTTNCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 HCAR3 537/4885LMNA 2692/4885UTS2R 632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.